AntiCancer Inc., of San Diego, said it was granted four U.S patents covering technology that enables tumor cells of any type, including human, to be imaged by their fluorescence in animal models.

Corixa Corp., of Seattle, said it received three U.S. patents. U.S. Patent No. 6,251,362 covers the administration of radiopharmaceutical compounds for the therapy of cancer and other diseases. U.S Patent Nos. 6,262,245 and 6,261,562 cover DNA sequences and methods of use for multiple prostate antigens potentially useful as vaccine or antibody targets.

CV Therapeutics Inc., of Palo Alto, Calif., received a notice of allowance from the U.S. Patent and Trademark Office for a method of using ranolazine sustained-release formulations, including the formulation used in the Marisa and Carisa studies, for the treatment of chronic angina.

GeneLink Inc., of Margate, N.J., said it filed a U.S. patent application for its proprietary genetic profiling method to predict an individual¿s susceptibility to osteopenia, a condition that often leads to osteoporosis.

Idun Pharmaceuticals Inc., of San Diego, said it was granted four U.S. patents. U.S. Patent Nos. 6,251,614 and 6,270,980 titled ¿Rapid Methods for Identifying Modifiers of Cellular Apoptosis Activity¿ provide a rapid method for determining the specific apoptotic activity of a cell and identifying compounds that induce or inhibit apoptosis. U.S. Patents Nos. 6,271,361 and 6,274,318 titled ¿Apoptotic Protease Mch6, Nucleic Acids Encoding Same and Methods of Use¿ cover a nucleic acid sequence encoding caspase 9 and a method for identifying compounds that modulate caspase 9 activity.

Progen Industries Ltd., of Brisbane, Australia, and the Australian National University (ANU) in Canberra, Australia, said ANU received U.S. Patent No. 6,271,215, titled ¿Sulfated Oligosaccharides Having Anticoagulant/Antithrombotic Activity.¿ The patent covers the method of use of sulfated oligosaccharides, particularly Progen¿s PI-88, for the prevention and treatment of blood clots.

Transkaryotic Therapies Inc., of Cambridge, Mass., said it received U.S. Patent No. 6,270,989 titled ¿Protein Production and Delivery.¿ It covers the company¿s core technological base that is being used for a variety of purposes, including the production and delivery of protein therapeutics using methods including gene activation, homologous recombination and gene therapy.

Vasogen Inc., of Toronto, said it received U.S. Patent No. 6,258,357 titled ¿Inhibition of Graft-versus-Host Disease¿ covering the application of the company¿s technology for the prevention of graft-vs.-host disease, a potentially fatal complication of bone marrow transplantation.

Xencor Inc., of Monrovia, Calif., said it received U.S. Patent Nos. 6,188,965 and 6,269,312, both titled ¿Apparatus and Method for Automated Protein Design,¿ expanding the company¿s patent estate for its protein design automation technology.

No Comments